Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital
Objetive: The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia. Methods: A retrospective review was performed of 100 non-electronic records of patients with...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2013-06-01
|
| Series: | Revista Brasileira de Hematologia e Hemoterapia |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000300174&lng=en&tlng=en |
| _version_ | 1819137370451083264 |
|---|---|
| author | Samuel Roosevelt Campos dos Reis Acy Telles de Souza Quixada Sammara Tavares Nunes Danielle Maria Camelo Cid Jacqueline Holanda de Souza Clara Maria Bastos Eloy da Costa Carolina Bizelli Silveira David Antonio Camelo Cid Mariana Fatima Cabral de Oliveira |
| author_facet | Samuel Roosevelt Campos dos Reis Acy Telles de Souza Quixada Sammara Tavares Nunes Danielle Maria Camelo Cid Jacqueline Holanda de Souza Clara Maria Bastos Eloy da Costa Carolina Bizelli Silveira David Antonio Camelo Cid Mariana Fatima Cabral de Oliveira |
| author_sort | Samuel Roosevelt Campos dos Reis |
| collection | DOAJ |
| description | Objetive: The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia. Methods: A retrospective review was performed of 100 non-electronic records of patients with Ph+ chronic myeloid leukemia treated with imatinib mesylate. The study period was from January 2001 to January2011. Data were analyzed by Chi-Square and Correspondence analysis using the Statistical Analysis System software package. Results: At the beginning of treatment 41% of patients were in advanced stages of the disease. The unavailability of the drug (44.8%) and myelotoxicity (25.7%) were the most frequent reasons for interruption. The adherence rate was < 90% in 47% of the cases. The low adherence influenced the cytogenetic response (p-value = 0.020) and molecular response (p-value = 0.001). Very high adherence (> 95%) induced complete cytogenetic response, major cytogenetic response and major molecular response. Conclusion: The population of this study obtained lower-than-expected therapeutic responses compared to other studies. |
| first_indexed | 2024-12-22T10:49:48Z |
| format | Article |
| id | doaj.art-0d66fd5bf0f94927b70ccc5b5f2ff2ed |
| institution | Directory Open Access Journal |
| issn | 1806-0870 |
| language | English |
| last_indexed | 2024-12-22T10:49:48Z |
| publishDate | 2013-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Revista Brasileira de Hematologia e Hemoterapia |
| spelling | doaj.art-0d66fd5bf0f94927b70ccc5b5f2ff2ed2022-12-21T18:28:49ZengElsevierRevista Brasileira de Hematologia e Hemoterapia1806-08702013-06-0135317417910.5581/1516-8484.20130053S1516-84842013000300174Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospitalSamuel Roosevelt Campos dos ReisAcy Telles de Souza QuixadaSammara Tavares NunesDanielle Maria Camelo CidJacqueline Holanda de SouzaClara Maria Bastos Eloy da CostaCarolina Bizelli SilveiraDavid Antonio Camelo CidMariana Fatima Cabral de OliveiraObjetive: The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia. Methods: A retrospective review was performed of 100 non-electronic records of patients with Ph+ chronic myeloid leukemia treated with imatinib mesylate. The study period was from January 2001 to January2011. Data were analyzed by Chi-Square and Correspondence analysis using the Statistical Analysis System software package. Results: At the beginning of treatment 41% of patients were in advanced stages of the disease. The unavailability of the drug (44.8%) and myelotoxicity (25.7%) were the most frequent reasons for interruption. The adherence rate was < 90% in 47% of the cases. The low adherence influenced the cytogenetic response (p-value = 0.020) and molecular response (p-value = 0.001). Very high adherence (> 95%) induced complete cytogenetic response, major cytogenetic response and major molecular response. Conclusion: The population of this study obtained lower-than-expected therapeutic responses compared to other studies.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000300174&lng=en&tlng=enLeukemia, myelogenous, chronic, BCR-ABL positive/drug therapyPiperazines/therapeutic useMedication adherenceFusion Proteins, bcr-abl/geneticTreatment outcome |
| spellingShingle | Samuel Roosevelt Campos dos Reis Acy Telles de Souza Quixada Sammara Tavares Nunes Danielle Maria Camelo Cid Jacqueline Holanda de Souza Clara Maria Bastos Eloy da Costa Carolina Bizelli Silveira David Antonio Camelo Cid Mariana Fatima Cabral de Oliveira Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital Revista Brasileira de Hematologia e Hemoterapia Leukemia, myelogenous, chronic, BCR-ABL positive/drug therapy Piperazines/therapeutic use Medication adherence Fusion Proteins, bcr-abl/genetic Treatment outcome |
| title | Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital |
| title_full | Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital |
| title_fullStr | Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital |
| title_full_unstemmed | Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital |
| title_short | Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital |
| title_sort | adherence to treatment with imatinib in chronic myeloid leukemia a study of the first decade of responses obtained at a brazilian hospital |
| topic | Leukemia, myelogenous, chronic, BCR-ABL positive/drug therapy Piperazines/therapeutic use Medication adherence Fusion Proteins, bcr-abl/genetic Treatment outcome |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000300174&lng=en&tlng=en |
| work_keys_str_mv | AT samuelrooseveltcamposdosreis adherencetotreatmentwithimatinibinchronicmyeloidleukemiaastudyofthefirstdecadeofresponsesobtainedatabrazilianhospital AT acytellesdesouzaquixada adherencetotreatmentwithimatinibinchronicmyeloidleukemiaastudyofthefirstdecadeofresponsesobtainedatabrazilianhospital AT sammaratavaresnunes adherencetotreatmentwithimatinibinchronicmyeloidleukemiaastudyofthefirstdecadeofresponsesobtainedatabrazilianhospital AT daniellemariacamelocid adherencetotreatmentwithimatinibinchronicmyeloidleukemiaastudyofthefirstdecadeofresponsesobtainedatabrazilianhospital AT jacquelineholandadesouza adherencetotreatmentwithimatinibinchronicmyeloidleukemiaastudyofthefirstdecadeofresponsesobtainedatabrazilianhospital AT claramariabastoseloydacosta adherencetotreatmentwithimatinibinchronicmyeloidleukemiaastudyofthefirstdecadeofresponsesobtainedatabrazilianhospital AT carolinabizellisilveira adherencetotreatmentwithimatinibinchronicmyeloidleukemiaastudyofthefirstdecadeofresponsesobtainedatabrazilianhospital AT davidantoniocamelocid adherencetotreatmentwithimatinibinchronicmyeloidleukemiaastudyofthefirstdecadeofresponsesobtainedatabrazilianhospital AT marianafatimacabraldeoliveira adherencetotreatmentwithimatinibinchronicmyeloidleukemiaastudyofthefirstdecadeofresponsesobtainedatabrazilianhospital |